Serum triglycerides, the liver and the pancreas

Current Opinion in Lipidology

Volumn 11, Issue 4, 2000, Pages 377-382

  Miller, J Paul ^a  

^a WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA INTERFERON; AMIODARONE; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHYLOMICRON; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; INSULIN; PROTEINASE INHIBITOR; STATIN; TAMOXIFEN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ALCOHOL CONSUMPTION; DIABETES MELLITUS; FAT INTAKE; FATTY LIVER; GENETIC DISORDER; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIVER; LIVER FUNCTION; PANCREAS; PANCREATITIS; PARENTERAL NUTRITION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIOXIDANTS; BIOPSY; FATTY LIVER; HUMANS; HYPERTRIGLYCERIDEMIA; LIVER; PANCREATITIS; PROGNOSIS; SYNDROME; TRIGLYCERIDES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033852433     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200008000-00006     Document Type: Review

References (47)

1. 1 Hewson W. An experimental enquiry into the properties of the blood with remarks on some of its morbid appearances and an appendix relating to the discovery of the lymphatic system in birds, fish and the animals called amphibious. Chapter VI. Titled 'Of the serum of the blood, and particularly of the milk-like serum'. London: Cadell; 1771:78-90.
2. 2 Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: The metabolic and molecular bases of inherited disease, 6th ed, vol II. Scriver CR, Beaudet AL, Sly WS, Valle D (editors). New York: McGraw-Hill; 1995. pp. 1913-1932.
3. 3 Fortson MR, Freedman SN, Webster PD. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90:2134-2139.
4. 4 Miller JP. The chylomicronaemia syndrome. In: Hyperlipidaemia in childhood, 1st ed. Neil HAW, Rees A, Taylor (editors). London: Royal College of Physicians; 1996. pp. 17-26.
5. 5 Bhatnagar D. Hypertriglyceridaemia. In: Lipoproteins in health and disease, 1st ed. Betteridge DJ, Illingworth DR, Shepherd J (editors). London: Arnold; 1999. pp. 737-751. This is an excellent all-embracing review of hypertriglyceridaemia, including the chylomicronaemia syndrome.
6. 6 Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 1997; 44:745-749.
7. 7 Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998; 83:1633-1635.
8. 8 Fernandez-Miranda C, Castellano G, Guijarro C, et al. Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. Am J Gastroenterol 1998; 93:1901-1904.
9. 9 Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidaemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100:700-705. This is one of the larger studies that examined the effects on lipids and lipoproteins of different PIs in HIV patients.
10. 10 Echevarria KL, Hardin TC, Smith JC. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33:859-863. This is a case report of severe hypertriglyceridaemia in a patient treated with antiretroviral therapy for HIV.
11. 11 Clark Perry R, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides and pancreatitis. Clin Infect Dis 1999; 28:161-162. A case report of severe hypertriglyceridaemia in a patient treated with antiretroviral therapy for HIV is presented.
12. 12 Henry K, Melroe H, Huebesch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
13. 13 Henry K, Melroe H, Huebesch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities [letter]. Lancet 1998; 352:1031-1032.
14. 14 Melroe NH, Kopaczewski J, Henry K, Huebsch J. Intervention for hyperlipidemia associated with protease inhibitors. J Assoc Nurses AIDS Care 1999; 10:55-69. This is an uncontrolled study of the effects of interventions with diet and drugs to ameliorate the dyslipidaemia that is associated with PIs used for the treatment of HIV infection.
15. 15 Wierzbicki AS, Reynolds TM, Crook MA, et al. Lipid lowering therapy in patients with HIV infection [letter]. Lancet 1998; 352:1782.
16. 16 Stocker DN, Meier PJ, Stoller R, Fattinger KE. 'Buffalo hump' in HIV-1 infection. Lancet 1998; 352:320-321.
17. 17 Losowsky MS, Jones DP, Davidson CS, Lieber CS. Studies of alcoholic hyperlipemia and its mechanism. Am J Med 1963; 35:794-803.
18. 18 Baraona E, Lieber CS. Alcohol and lipids. Recent Dev Alcoholism 1998; 14:97-134.
19. 19 Crook MA, Sankaralingam A. Total parenteral nutrition in the chylomicronemia syndrome and acute pancreatitis. Nutrition 1999; 15:299-301. This is a case report of patient with chylomicronaemia and pancreatitis managed with 'fat-free' total parenteral nutrition.
20. 20 Kollef MH, McCormack MT, Caras WE, et al. The fat overload syndrome: successful treatment with plasma exchange. Ann Intern Med 1990; 112:545-546.
21. 21 Lennertz A, Parhofer KG, Samtleben W, Bosch T. Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apheresis 1999; 3:227-233. Use of plasma exchange in five patients with pancreatitis complicating massive hypertriglyceridaemia is described.
22. 22 Piolot A, Nadler F, Cavallero E, et al. Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis. Pancreas 1996; 13:96-99.
23. 23 Breckenridge WC, Little JA, Steiner G, et al. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med 1978; 298:1265-1273.
24. 24 Watts GF, Mitropoulos KA, Al-Bahrani A, et al. Lecithin-cholesterol acyltransferase deficiency presenting with acute pancreatitis: effect of infusion of normal plasma on triglyceride-rich lipoproteins. J Intern Med 1995; 238:137-141.
25. 25 Jabbar MA, Zuhri-Yafi MI, Larrea J. Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia. J Am Coll Nutr 1998; 17:458-461.
26. 26 Mizushima T, Ochi K, Matsumura N, et al. Prevention of hyperlipidemic acute pancreatitis during pregnancy with medium-chain triglyceride nutritional support. Int J Pancreatol 1998; 23:187-192.
27. 27 Rouis M, Dugi KA, Previato L, et al. Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol 1997; 17:1400-1406.
28. 28 Heaney AP, Sharer N, Rameh B, et al. Prevention of recurrent pancreatitis in familial lipoprotein lipase deficiency with high-dose antioxidant therapy. J Clin Endocrinol Metab 1999; 84:1203-1205. This important study showed dramatic reduction in number of attacks of pancreatitis in three patients with lipoprotein lipase deficiency taking high-dose antioxidant treatment.
29. 29 Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
30. 30 James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29:495-501.
31. 31 Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19:221-229. This is a detailed current review of the NASH syndrome.
32. 32 James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353:1634-1636. This leading article contains a useful summary of a recent US National Institutes of Health consensus symposium about NASH.
33. 33 Cotrim HP, Andrade ZA, Parana R, et al. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999; 19:299-304. This study suggests that industrial exposure to petrochemicals may cause NASH.
34. 34 Malloy MJ, Kane JP. Disorders involving deficiencies of lipoproteins that contain Bapolipoproteins. In: Lipoproteins in health and disease, 1st ed. Betteridge DJ, Illingworth DR, Shepherd J (editors). London: Arnold; 1999:863-877. An authoritative review of all aspects of abetalipoproteinaemia and related disorders is provided.
35. 35 Marceau P, Biron S, Hould F-S, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84:1513-1517. This paper describes NASH and insulin resistance in severe obesity.
36. 36 Knobler H, Schattner A, Zhornicki T, et al. Fatty liver: an additional and treatable feature of the insulin resistance syndrome. Q J Med 1999; 92:73-79. This important study of 48 patients with persistent liver function abnormalities suggests that NASH is a common feature of the insulin resistance syndrome.
37. 37 Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29:664-669. NASH may be a significant cause of cryptogenic cirrhosis.
38. 38 Powell EE, Cooksley WGE, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74-80.
39. 39 Teli MR, James OFW, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22:1714-1719.
40. 40 Hulcrantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21:109-113.
41. 41 Van Ness M, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111:473-478.
42. 42 Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989; 9:193-197.
43. 43 Saverymuttu SH, Joseph AEA, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Lancet 1986; 292:13-15.
44. 44 Mathiesen UL, Franzen LE, Fryden A, et al. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999; 34:85-91. A liver biopsy study of 150 asymptomatic patients with persistent mild-to-moderate abnormalities of liver function is presented.
45. 45 Grant A, Neuberger J. Guidance on the use of liver biopsy in clinical practice. Gut 1999; 45(Suppl IV):IV1-IV11. These authoritative, evidence-based guidelines were produced on behalf of the British Society of Gastroenterology.
46. 46 Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatol 1996; 23:1464-1467.
47. 47 Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [letter]. J Hepatol 1999; 31:384. This brief report suggests that gemfibrozil not only lowers triglycerides, but also improves the liver function abnormality in patients with NASH.